Literature DB >> 11524451

Effect of aging and diabetes on the enteroinsular axis.

J Korosi1, C H McIntosh, R A Pederson, H U Demuth, J F Habener, R Gingerich, J M Egan, D Elahi, G S Meneilly.   

Abstract

BACKGROUND: The current studies were designed to examine the effect of aging and diabetes on the enteroinsular axis.
METHODS: Healthy young control subjects (n = 10 young; age 23 +/- 1 years; body mass index [BMI] 24 +/- 1 kg/m(2)), healthy elderly subjects (n = 10; age 80 +/- 2 years; BMI 26 +/- 1 kg/m(2)), and elderly patients with type 2 diabetes (n = 10; age 76 +/- 2 years; BMI 26 +/- 2 kg/m(2)) underwent a 3-hour oral glucose tolerance test (glucose dose 40 gm/m(2)).
RESULTS: Insulin responses were not different between young controls and elderly patients with diabetes but were significantly lower in elderly patients with diabetes and young controls than in elderly controls (young control: 178 +/- 27 pM; elderly control: 355 +/- 57 pM; elderly diabetes: 177 +/- 30 pM; p <.05 elderly control vs young control and elderly diabetes). Total glucagon-like peptide 1 (GLP-1) responses were not significantly different between young and elderly controls and patients with diabetes (young control: 15 +/- 2 pM; old control: 8 +/- 2 pM; elderly diabetes: 12 +/- 3 pM; p = ns). Active GLP-1 responses were also not different between young and elderly controls and patients with diabetes (young control: 5 +/- 1 pM; old control: 6 +/- 1 pM; elderly diabetes: 7 +/- 1 pM; p = ns). However, the difference between total and active GLP levels was significantly greater in the young controls (young control: 10 +/- 2 pM; old control: 2 +/- 2 pM; elderly diabetes: 4 +/- 2 pM; p <.05, young vs elderly). Glucose-dependent insulinotropic polypeptide responses were not different between young and elderly controls and between elderly controls and patients with diabetes but were significantly higher in elderly patients with diabetes than in young controls (young control: 97 +/- 12 pM; elderly control: 121 +/- 16 pM; elderly diabetes: 173 +/- 27 pM; p <.05, young vs elderly diabetes). Glucagon responses were reduced in elderly controls but were similar in young controls and elderly patients with diabetes (young control: 15 +/- 1 pM; elderly control: 9 +/- 1 pM; elderly diabetes: 16 +/- 1 pM; p <.01 elderly control vs young control and elderly diabetes). Dipeptidyl peptidase IV levels were lower in both elderly controls and patients with diabetes when compared with young controls (young control: 0.17 +/- 0.01; elderly control: 0.15 +/- 0.01; elderly diabetes: 0.15 +/- 0.01 DeltaOD/20 minutes; p <.05, elderly vs young).
CONCLUSIONS: We conclude that normal aging and diabetes are associated with multiple changes in the enteroinsular axis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524451     DOI: 10.1093/gerona/56.9.m575

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  14 in total

1.  Effect of aging on transpyloric flow, gastric emptying, and intragastric distribution in healthy humans--impact on glycemia.

Authors:  Deirdre O'Donovan; Trygve Hausken; Yong Lei; Antonietta Russo; Jennifer Keogh; Michael Horowitz; Karen L Jones
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

2.  Older Subjects With β-Cell Dysfunction Have an Accentuated Incretin Release.

Authors:  José de Jesús Garduno-Garcia; Amalia Gastaldelli; Ralph A DeFronzo; Raweewan Lertwattanarak; Jens J Holst; Nicolas Musi
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

3.  Decreased glucagon-like peptide-1 receptor immunoreactivity in the dentate granule cell layer from adult in the gerbil hippocampus.

Authors:  Choong Hyun Lee; Ki-Yeon Yoo; Pan Dong Ryu; Joon Ha Park; Jung Hoon Choi; Sookon Kim; In Koo Hwang; Young-Myeong Kim; Moo-Ho Won
Journal:  Cell Mol Neurobiol       Date:  2010-12-09       Impact factor: 5.046

Review 4.  Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk.

Authors:  Chee W Chia; Josephine M Egan; Luigi Ferrucci
Journal:  Circ Res       Date:  2018-09-14       Impact factor: 17.367

Review 5.  Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.

Authors:  S Calanna; M Christensen; J J Holst; B Laferrère; L L Gluud; T Vilsbøll; F K Knop
Journal:  Diabetologia       Date:  2013-02-03       Impact factor: 10.122

6.  Appetite-related gut peptides, ghrelin, PYY, and GLP-1 in obese women with and without binge eating disorder (BED).

Authors:  Allan Geliebter; Sami A Hashim; Marci E Gluck
Journal:  Physiol Behav       Date:  2008-04-13

Review 7.  Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?

Authors:  Wellington Santana da Silva Júnior; Amélio Fernando de Godoy-Matos; Luiz Guilherme Kraemer-Aguiar
Journal:  Biomed Res Int       Date:  2015-06-04       Impact factor: 3.411

8.  Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects.

Authors:  Radwan H Ahmed; Hasniza Zaman Huri; Zaid Al-Hamodi; Sameer D Salem; Sekaran Muniandy
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

9.  Glucagon-like peptide-1 secretory function as an independent determinant of blood pressure: analysis in the Tanno-Sobetsu study.

Authors:  Mayumi Yoshihara; Hiroshi Akasaka; Hirofumi Ohnishi; Takayuki Miki; Tetsuaki Furukawa; Satoshi Yuda; Shigeyuki Saitoh; Tetsuji Miura
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

Review 10.  Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.

Authors:  Salvatore Calanna; Mikkel Christensen; Jens J Holst; Blandine Laferrère; Lise L Gluud; Tina Vilsbøll; Filip K Knop
Journal:  Diabetes Care       Date:  2013-10       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.